Galderma is an emerging pure-play dermatology category leader present in approximately 90 countries, with a science-based portfolio spanning Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Founded in 1981, the company says it has dedicated its focus to the skin and to meeting consumer and patient needs in partnership with healthcare professionals. Galderma announced a private placement of approximately USD 1 billion in newly issued shares to strengthen its balance sheet and further accelerate organic growth driven by its integrated dermatology strategy. The company reported it continues to perform strongly, delivering at the top end of its 2022 revenue guidance with double digit growth, and it expects continued strong growth momentum in 2023. Management says the proceeds will be used to support the company’s organic growth plans. An initial public offering remains the likely next step in Galderma’s ambition to become the leading dermatology company in the world.

Total raised

$1.0B

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2023